Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Ablynx N.V, Merck deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Antibodies Ablynx said it and partner Merck jointly extended a 2012 deal to develop and commercialize Ablynxs …

    Published on 4/13/2015
  • ADC Therapeutics, Genmab deal

    ADC Therapeutics S.a.r.l., Lausanne, Switzerland Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Cancer Genmab did not exercise its co-development right for HuMax-TAC-ADC under a June 2013 deal to …

    Published on 4/13/2015
  • Alere Inc, Qiagen deal

    Alere Inc. (NYSE:ALR), Waltham, Mass. Qiagen N.V. (Xetra:QIA;NASDAQ:QGEN), Venlo, the Netherlands Business: Cancer Qiagen purchased circulating tumor cell (CTC) detection technology and two diagnostics -- AdnaTest …

    Published on 4/13/2015
  • Alkermes, Recro deal

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Business: Neurology Recro Pharma will purchase from Alkermes IV/IM meloxicam and its related business unit and manufacturing …

    Published on 4/13/2015
  • Arvinas, Merck deal

    Arvinas LLC, New Haven, Conn. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Proteomics Arvinas granted Merck an exclusive, multiyear license to use the biotechs proteolysis-targeting chimeric molecule…

    Published on 4/13/2015
  • AstraZeneca, Joslin Diabetes Center deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Joslin Diabetes Center, Boston, Mass. Business: Endocrine/Metabolic AstraZenecas MedImmune LLC biologics unit and the center partnered to develop candidates to treat …

    Published on 4/13/2015
  • BHV Pharma, Islet Sciences deal

    BHV Pharma Inc., Research Triangle Park, N.C. Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Business: Endocrine/Metabolic, Hepatic Islet Sciences and BHV Pharma will terminate a proposed merger to form Avogenx Inc. …

    Published on 4/13/2015
  • Biodesix, Inivata deal

    Biodesix Inc., Broomfield, Colo. Inivata Ltd., Cambridge, U.K. Business: Diagnostic The companies partnered to develop and commercialize blood-based tests for clinical applications in lung cancer. Inivata is …

    Published on 4/13/2015
  • Biophage Pharma Inc, Phagelux deal

    Biophage Pharma Inc. (NEX:BUG), Montreal, Quebec Phagelux Inc., Nanjing, China Business: Other Phageluxs Phagelux Canada Inc. subsidiary will purchase IP and phage and bacterial libraries from Biophage for $200,000 in …

    Published on 4/13/2015
  • C2N Diagnostics, AbbVie deal

    C2N Diagnostics LLC, St. Louis, Mo. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Neurology C2N granted AbbVie an exclusive, worldwide license to develop and commercialize a portfolio of antibodies against …

    Published on 4/13/2015
  • Cancer Research UK, EPSRC deal

    Cancer Research UK, London, U.K. Engineering and Physical Sciences Research Council, Swindon, U.K. Business: Cancer Cancer Research UK and EPSRC partnered to co-fund multidisciplinary cancer research projects. The …

    Published on 4/13/2015
  • Egalet Corp, Shionogi deal

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Business: Neurology, Drug delivery Egalet received a $10 million milestone payment from Shionogi under the companies 2013 deal to …

    Published on 4/13/2015
  • EUSA Pharma, Jazz Pharmaceuticals deal

    EUSA Pharma, Hemel Hempstead, U.K. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Neurology, Other Essex Bidco Ltd. acquired five approved specialty hospital products and related commercial …

    Published on 4/13/2015
  • Exact Sciences Corp, Ironwood deal

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Diagnostic The companies will co-promote Exacts colorectal cancer test Cologuard in the U.S. …

    Published on 4/13/2015
  • Flexus Biosciences, Bristol-Myers deal

    Flexus Biosciences Inc., San Carlos, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Bristol-Myers Squibb completed its acquisition of Flexus for $800 million up front and up to $450 million …

    Published on 4/13/2015
  • Glide Pharma, Pfenex deal

    Glide Pharma Technologies Ltd., Abingdon, U.K. Pfenex Inc. (NYSE-M:PFNX), San Diego, Calif. Business: Infectious, Drug delivery NIHs National Institute of Allergy and Infectious Disease (NIAID) exercised its option to …

    Published on 4/13/2015
  • Juno Therapeutics Inc, Novartis, St. Jude Childrens Research Hospital, University of Pennsylvania deal

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland St. Jude Childrens Research Hospital, Memphis, Tenn. University of Pennsylvania, Philadelphia, Pa. Business: …

    Published on 4/13/2015
  • LabCorp, Sihuan deal

    Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460), Haikou, China Business: Pharmaceuticals Sihuans Shandong XuanZhu Pharma Co. Ltd. subsidiary …

    Published on 4/13/2015
  • Merck & Co. Inc, Akorn deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Akorn Inc. (NASDAQ:AKRX), Lake Forest, Ill. Business: Infectious InSite Vision Inc. (OTCBB:INSV, Alameda, Calif.) settled a lawsuit against Mylan N.V. (NASDAQ:MYL, …

    Published on 4/13/2015
  • Midatech Pharma, MonoSol Rx deal

    Midatech Pharma plc (LSE:MTPH), Abingdon, U.K. MonoSol Rx LLC, Warren, N.J. Business: Drug delivery, Endocrine/Metabolic Midatech and MonoSols MidaSol Therapeutics LLP JV partnered with an undisclosed pharmaceutical …

    Published on 4/13/2015
  • Myriad Genetics Inc, BioMarin deal

    Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Business: Cancer The companies expanded a 2013 deal and BioMarin will use Myriads myChoice Homologous …

    Published on 4/13/2015
  • Ophthotech Corp, Novartis deal

    Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Ophthalmic Ophthotech received a second $50 million payment from Novartis under a May 2014 deal granting the …

    Published on 4/13/2015
  • Perrigo, Mylan deal

    Perrigo Co. plc (NYSE:PRGO;Tel Aviv:PRGO), Dublin, Ireland Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Autoimmune, Generics Generics maker Mylan proposed to acquire Perrigo for $205 per share, or $28.9 billion, …

    Published on 4/13/2015
  • Pulmatrix, Ruthigen deal

    Pulmatrix Inc., Lexington, Mass. Ruthigen Inc. (NASDAQ:RTGN), Santa Rosa, Calif. Business: Pulmonary, Drug delivery Pulmatrix will reverse-merge with Ruthigen, with Pulmatrix shareholders owning 81% of the surviving …

    Published on 4/13/2015
  • Qiagen N.V, Tokai deal

    Qiagen N.V. (Xetra:QIA;NASDAQ:QGEN), Venlo, the Netherlands Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Business: Pharmacogenetics Qiagen and Tokai partnered to co-develop a liquid biopsy circulating …

    Published on 4/13/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993